TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28316261

Group type: EXPERIMENTAL
Intervention: Reduced strength training with one session per week (RST1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Reduced strength training with two sessions per week (RST2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ceased training (CT)
Number of subjects: 33
Study: 25716189

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Randomized working memory training
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Self-selected change in training task difficulty
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study: 24568978

Group type: EXPERIMENTAL
Intervention: Office-based nasolacrimal duct probing using topical anesthesia
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Office-based nasolacrimal duct probing
Number of subjects: 304
Study: 23770182

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 18113
Study: 20074388

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet with weekly group meetings
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 109
Study: 18952147

Group type: EXPERIMENTAL
Intervention: Anodal DC brain polarization of right parietal cortex, intensity 2.0 mA for 20 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 17038247

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) or EN supplemented with parenteral nutrition (EN+PN)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 65
Study: 12505962

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 50
Study: 10883352

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study: 8878242

Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 341) once daily for 5 days
Number of subjects: 677

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (n = 336) three times daily for 10 days
Number of subjects: 677
Study: 8315799

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B, n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL, n = 41)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL)
Number of subjects: 82
Study: 3788741

Group type: EXPERIMENTAL
Intervention: Two 400 mg oral doses for a single day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three 200 mg oral doses for three days
Number of subjects: 30
Study: 29922099

Group type: EXPERIMENTAL
Intervention: Annular closure device (ACD)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-Trial group (no ACD)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-Trial group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Trial group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study: 27612167

Group type: EXPERIMENTAL
Intervention: Storytelling as part of a residential cancer rehabilitation intervention
Number of subjects: 20
Study: 25551944

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patient group (chronic anal fissure)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison between patient group and control group
Number of subjects: 41
Study: 24184336

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) donation
Number of subjects: 332

Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cell (PBSC) donation
Number of subjects: 332
Study: 22488405

Group type: EXPERIMENTAL
Intervention: HIV-RAAP intervention
Number of subjects: 0
Study: 20664906

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day for days 1-10; 300 mg on day 11)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17971588

Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy (methotrexate and cytarabine)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Intensive triple IT chemotherapy (methotrexate, cytarabine and hydrocortisone) without CRT
Number of subjects: 164
Study: 15820996

Group type: EXPERIMENTAL
Intervention: Resolve to Stop the Violence Project (RSVP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control dorm (traditional jail practices)
Number of subjects: 56
Study: 12170410

Group type: EXPERIMENTAL
Intervention: 2-l PEG-EL solution
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 200
Study: 10558394

Group type: EXPERIMENTAL
Intervention: Substance use intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary least squares (OLS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multilevel estimators
Number of subjects: 0
Study: 10163426

Group type: EXPERIMENTAL
Intervention: Zopiclone for 14 days
Number of subjects: 458

Group type: COMPARATOR
Intervention: Zopiclone for at least 12 months
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 458
Study: 1829439

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-flux polyacrylonitrile (AN 69) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-flux polyacrylonitrile (AN 69) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low heparin regimen (LHR)
Number of subjects: 8
Study: 6360178

Group type: EXPERIMENTAL
Intervention: Lymphoplasmapheresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control procedure (sham apheresis)
Number of subjects: 20
Study: 30127374

Group type: EXPERIMENTAL
Intervention: Flaxseed consumption (30 g/day) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study: 29607568

Group type: EXPERIMENTAL
Intervention: Geriatric education for nursing home staff
Number of subjects: 629

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Special care unit in nursing home
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Fall in the last 12 months
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Psychiatric advice and/or hospitalization in a psychiatric unit
Number of subjects: 629
Study: 26837536

Group type: EXPERIMENTAL
Intervention: Instructional Card
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Standard post-operative instruction)
Number of subjects: 80
Study: 24633366

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 1)
Number of subjects: 7263

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 2)
Number of subjects: 7263

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 3)
Number of subjects: 7263

Group type: COMPARATOR
Intervention: EV71 vaccine
Number of subjects: 7263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7263
Study: 22427749

Group type: EXPERIMENTAL
Intervention: Planned Elective Repeat Caesarean (ERC)
Number of subjects: 2345

Group type: COMPARATOR
Intervention: Planned Vaginal Birth after Caesarean (VBAC)
Number of subjects: 2345
Study: 20374349

Group type: EXPERIMENTAL
Intervention: Serum CTX bone marker feedback (BMF) at 3 months
Number of subjects: 596

Group type: COMPARATOR
Intervention: No BMF
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Serum CTX BMF
Number of subjects: 596
Study: 18232240

Group type: EXPERIMENTAL
Intervention: Therapeutic, psychosocial engagement strategy (ethnographic and motivational interviewing)
Number of subjects: 0
Study: 16039195

Group type: EXPERIMENTAL
Intervention: High-dose insulin treatment (short-acting insulin 1 IU.kg(‐1).h(‐1) with 30% glucose 1.5 mL.kg(‐1).h(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose insulin treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control treatment (saline)
Number of subjects: 40
Study: 12039085

Group type: EXPERIMENTAL
Intervention: Informed about the VOKS results (report group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not informed about the VOKS results (control group)
Number of subjects: 0
Study: 9808873

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (100 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg i.v. prior to thrombolytic therapy and 325 mg/day orally)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 41
Study: 7655770

Group type: EXPERIMENTAL
Intervention: Oral sulpiride (2 x 50 mg capsules, 200 mg tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous sulpiride (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Model based on 2 Weibull-functions
Number of subjects: 12
Study: 2070512

Group type: EXPERIMENTAL
Intervention: Telelab Personal Blood Pressure Transmitter
Number of subjects: 92

Group type: COMPARATOR
Intervention: Mercury sphygmomanometers
Number of subjects: 92
Study: 6311774

Group type: EXPERIMENTAL
Intervention: bolus 6-methylprednisolone (B/6-MP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: corticotrophin (ACTH)
Number of subjects: 30
Study: 31065111

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on day 1 and day 8)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Dacarbazine (850, 1000, or 1200 mg/m² intravenously every 21 days)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 309

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 309
Study: 29797389

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal-bolus therapy (BBT)
Number of subjects: 0
Study: 27333022

Group type: EXPERIMENTAL
Intervention: High total serum IgG levels
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: High total serum IgM levels
Number of subjects: 1367

Group type: COMPARATOR
Intervention: Basic risk model
Number of subjects: 1367
Study: 25103909

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waiting control (WC)
Number of subjects: 151
Study: 23095799

Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: ARB (doubled dose)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CCB (doubled dose)
Number of subjects: 95
Study: 19252451

Group type: EXPERIMENTAL
Intervention: 1 g SCE‐A cream (n = 150)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Matching placebo (n = 155)
Number of subjects: 305
Study: 17681970

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg kg(‐1) i.v. 5 min before induction of general anaesthesia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isotonic saline 5 min before induction of anaesthesia
Number of subjects: 17
Study: 16402012

Group type: EXPERIMENTAL
Intervention: Johnson's Baby products used daily for 8 weeks
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Johnson's Baby products used daily for 8 weeks in 186 newborns (92 female plus 94 male) aged 0-4 weeks
Number of subjects: 606
Study: 11978464

Group type: EXPERIMENTAL
Intervention: HPMC-lidocaine mixture (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pure HPMC 2.25% (n = 35)
Number of subjects: 70
Study: 9795882

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models for relaxing assumptions regarding covariate and statistical submodels
Number of subjects: 0
Study: 8599066

Group type: EXPERIMENTAL
Intervention: 2-1-1 schedule (one dose in right arm and one in left arm at day 0, one dose on days 7 and 21)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Variant schedule (double dose on day zero and another on day 14)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3 doses (2-1-1 schedule)
Number of subjects: 12
Study: 2807927

Group type: EXPERIMENTAL
Intervention: Urea-containing cream
Number of subjects: 0
Study: 162678

Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 (bromazepam)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 (bromazepam) during pregnancy
Number of subjects: 25
Study: 31790983

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin with MRD-negative status (CR/CRi)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (MRD-negative patients)
Number of subjects: 164
Study: 31006770

Group type: EXPERIMENTAL
Intervention: Mobile immunization team visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no mobile immunization team visit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall vaccination coverage among all HCWs
Number of subjects: 0
Study: 28349493

Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds (5 g daily throughout treatment)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 80
Study: 25956072

Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol FDC 5/5 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 22915784

Group type: EXPERIMENTAL
Intervention: RA(1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RA(4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RA(2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RA(3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PTV(2) and PTV(3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RA plans (RA(1-4))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RA(1) and RA(4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RA(2) and RA(3)
Number of subjects: 10
Study: 21593490

Group type: EXPERIMENTAL
Intervention: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamins B-6 3 mg, B-12 0.02 mg) and omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids 600 mg)
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1748
Study: 19912346

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BOTOX), maximum 200 units at baseline and month 3, plus oral placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topiramate (TOPAMAX), 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections
Number of subjects: 60
Study: 16978233

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 128
Study: 12828495

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 961

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 961
Study: 10931368

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) cases
Number of subjects: 28

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 28
Study: 9132744

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) dry powder inhaler 2 x 250 micrograms/d
Number of subjects: 169

Group type: COMPARATOR
Intervention: Flunisolide (FLUN) metered dose inhaler 2 x 500 micrograms/d
Number of subjects: 169
Study: 8454015

Group type: EXPERIMENTAL
Intervention: Inertial load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elastic spring load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stretched-spring load
Number of subjects: 10
Study: 3531315

Group type: EXPERIMENTAL
Intervention: sucralfate 2 g 2 i.d. (on waking and at bedtime)
Number of subjects: 77

Group type: COMPARATOR
Intervention: sucralfate 1 g 4 i.d. (1/2 h before meals and at bedtime)
Number of subjects: 77
Study: 29330940

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intralesional steroid injection
Number of subjects: 39
Study: 28391662

Group type: EXPERIMENTAL
Intervention: Test dentifrice (5% CSPS and sodium fluoride)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Comparator dentifrice (5% CSPS and sodium monofluorophosphate)
Number of subjects: 304
Study: 24211400

Group type: EXPERIMENTAL
Intervention: Combination of trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 114
Study: 23164667

Group type: EXPERIMENTAL
Intervention: Bilateral inferior alveolar nerve block (BIANB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard procedure (general anesthesia with postoperative morphine treatment)
Number of subjects: 30
Study: 20584355

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalteparin (as the least expensive option)
Number of subjects: 0
Study: 18563786

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative radiotherapy (PRT)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME) without preoperative radiotherapy (PRT)
Number of subjects: 785
Study: 16085588

Group type: EXPERIMENTAL
Intervention: F + 0 protocol (immediate administration of radiopharmaceutical after furosemide)
Number of subjects: 108

Group type: COMPARATOR
Intervention: F - 15 protocol (radiopharmaceutical administered 15 min after furosemide)
Number of subjects: 108

Group type: COMPARATOR
Intervention: F - 15 protocol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: F + 0 protocol
Number of subjects: 108
Study: 12166604

Group type: EXPERIMENTAL
Intervention: Combined program of weight loss, improvement of diet, increase of physical exercise and smoking cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10614061

Group type: EXPERIMENTAL
Intervention: ACTH 1-17 stimulation test
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 30
Study: 7546992

Group type: COMPARATOR
Intervention: Metoprolol 50-100 mg twice daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Xamoterol 100-200 mg twice daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both metoprolol and xamoterol
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 210
Study: 1741985

Group type: EXPERIMENTAL
Intervention: Preoperative interviews by a perioperative nurse
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preoperative interviews (control group)
Number of subjects: 60
Study: 6920252

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/dose) administered 72, 48, and 24 hours before delivery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/dose)
Number of subjects: 24
Study: 31652857

Group type: EXPERIMENTAL
Intervention: Exergaming intervention (once‐weekly 50‐minute sessions during recess for 8 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Regular recess (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exergaming intervention
Number of subjects: 81
Study: 28910200

Group type: EXPERIMENTAL
Intervention: 12-g β-alanine (12G)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-g β-alanine (6G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30
Study: 25695900

Group type: EXPERIMENTAL
Intervention: Access to online educational modules
Number of subjects: 37

Group type: COMPARATOR
Intervention: No access to online educational modules
Number of subjects: 37
Study: 23494053

Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated heparin (UFH)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2,500 IU low-molecular-weight heparin (LMWH, dalteparin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both heparin types
Number of subjects: 43
Study: 21436709

Group type: EXPERIMENTAL
Intervention: On-site training for nurse-midwives in intervention sites
Number of subjects: 2444
Study: 19565734

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with magnetic therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Simple magnetic therapy (Control)
Number of subjects: 82
Study: 18006969

Group type: EXPERIMENTAL
Intervention: Prostate biopsies for participants with a prostate specific antigen level of 1.5 ng/ml or more
Number of subjects: 1299
Study: 15994145

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d orally)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no tamoxifen)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 420
Study: 11937566

Group type: EXPERIMENTAL
Intervention: 600 mg BIRB 796 BS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg BIRB 796 BS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9704781

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine, 0.25%, 13 mL
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil, 10 microg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Epidural analgesia in the left lateral position
Number of subjects: 305
Study: 8582463

Group type: EXPERIMENTAL
Intervention: Morphine sulphate 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine sulphate 15 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lorazepam 1 mg (positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12